EI
HTGM

EAM Investors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

EAM Investors’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,586
Closed -$1.03M – 378
2018
Q1 		$1.03M Buy
+1,586
New +$1.19M 0.17% 204

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.4B AUM 36.82% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

EAM Investors's HTGM Position: Q2 2018 in Review

EAM Investors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2018, closing a stake of 1,586 shares — an estimated $1.03M sold.

EAM Investors first reported a position in HTGM in Q1 2018 and held it in 1 quarter. The position peaked at $1.03M in Q1 2018. 44 funds tracked by Wall St. Rank hold HTGM as of Q2 2018.

  • EAM Investors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • EAM Investors sold 1,586 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2018, an estimated $1.03M.
  • EAM Investors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • EAM Investors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.03M in Q1 2018.
  • 44 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2018.

Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.